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Abstract Bone-resorbing osteoclasts are formed through
fusion of mononucleated precursors. Their choice of part-
ners during the fusion process remains unclear. We
hypothesized that osteoclasts are selective in their choice of
fusion partner and that this selectivity is based on hetero-
geneity among the cells with respect to their maturation
stage and their expression and cellular organization of
fusion factors. Support for this hypothesis was found from
immunofluorescence staining of the osteoclast fusion fac-
tors CD47, dendritic cell-specific transmembrane protein
(DC-STAMP), and syncytin-1. These stainings revealed
heterogeneous localization patterns of all three factors
within a given culture of osteoclasts. CD47 was found to be
localized primarily in small osteoclasts and preosteoclasts,
which were also positive for DC-STAMP but negative for
cathepsin K expression. A role of CD47 in the early osteo-
clast fusion steps was also suggested from experiments with
a CD47 blocking antibody, which resulted in an inhibition of
the fusion of small osteoclasts. Conversely, blocking of
connexin 43 affected the fusion of larger osteoclasts with
four or more nuclei. The suggestion that different fusion
factors function at different stages of osteoclast fusion
supports the idea of heterogeneity in the osteoclast popu-
lation; our results suggest that osteoclast fusion is indeed
based on heterogeneity. Considering the in vivo environ-
ment in which osteoclasts develop and fuse, our findings
seem very applicable and provide novel, important insight
into key issues in bone and fusion research.
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Introduction
Osteoclasts (OCs) are large multinucleated cells formed
through fusion of mononucleated precursors of monocytic
origin. OCs are responsible for resorption of bone during the
natural maintenance of bone homeostasis, and their forma-
tion is crucial for human health. In general, fusion between
cells is a common biological phenomenon that is funda-
mental in events like the fusion of sperm and oocyte during
fertilization and the multiple fusions of trophoblasts in the
placenta. Important fusion events are also the fusion of
myoblasts into muscle fibers and that of macrophages to
produce giant cells at chronic inflammatory sites [1–3].
Much effort has been devoted to identify the factors
involved in these different kinds of fusion, and some pro-
teins have been shown to be common to several of the fusion
processes studied. One of these proteins is the endogenous
retroviral-derived protein syncytin-1. The binding of this
protein to its receptor, alanine-, serine-, cysteine-preferring
neutral amino acid transporter 2 (ASCT2), gives rise to
conformational changes in syncytin-1 that pull the lipid
bilayers together and cause the cells to fuse [4]. Syncytin-1
is involved in human OC fusion [5] and human trophoblast
fusion [6, 7], and it has also been suggested to play a role in
the fusion of human myoblasts [8].
Another well-known fusion factor is CD47, which is an
ubiquitously expressed glycoprotein that interacts with
signal-regulatory protein alpha (SIRPa) as part of the
multinucleation process in both OCs and macrophages [9–
11]. The interaction between CD47 and SIRPa, which are
both members of the superfamily of immunoglobulins, also
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plays a role in the immunological recognition of ‘‘self’’ to
prevent macrophage phagocytosis [12]. This property
could make macrophages distinguish potential fusion
partners from matters to phagocytize, as previously sug-
gested [13, 14]. Like CD47, dendritic cell-specific trans-
membrane protein (DC-STAMP) is another important
fusion-related factor that has been demonstrated to be
important for the fusion of cells of monocytic origin [15–
17]. DC-STAMP is described as a central fusion mediator
in OCs because a variety of factors can regulate OC fusion
by affecting DC-STAMP expression [18]. Interestingly, it
has been demonstrated that in order for OC formation to
take place, the expression of DC-STAMP is only required
in one of two fusing partners [16]. It is noticeable that there
is significant diversity among the recognized fusion factors,
and the factor connexin 43 (Cx43) is unique in regard to
function compared to syncytin-1, CD47, and DC-STAMP.
Cx43 forms gap junctions, which allows intercellular
communication that has previously been shown to be
important to permit fusion of both trophoblasts, myoblasts,
and OCs [19–23].
Several studies have provided important details about OC
fusion factors and their importance to the fusion process.
This research has mainly been focused on the expression of
genes encoding potential fusion factors, in vitro blocking, or
overexpression [9, 10, 15, 19, 20]. In other cases, knockout
animal models were used [9, 11, 16, 17, 24, 25]. Common to
these studies is that the obtained results reflect the response
of the OC population as a whole in relation to the total gene
expression, the total change in OC number, or the end-point
effects on bone phenotype. Less emphasis has been placed on
how cells like OCs behave during a fusion event. It is clear
that fusion is a multistep process in which cells recognize and
migrate toward each other, then come into close proximity
and eventually fuse. However, how do the cells select their
fusion partners? Is some kind of selectivity involved in this
action? These questions naturally arise because under-
standing the preferences and behaviors of cells during fusion
is of biological and medical interest.
Mensah et al. [26] suggested that fusion among preos-
teoclasts (preOCs) is determined by cell-population heter-
ogeneity in relation to the presence or the absence of DC-
STAMP on the extracellular membrane. Likewise, a pat-
tern of complementarity regarding the location of syncytin-
1 was observed in OCs that were in close contact in
phagocytic cups where syncytin-1 was found to be up-
concentrated at the area of the membrane facing the fusion
partner [5]. Together, this recent research suggests that
heterogeneity does indeed exist in populations of fusing
(pre)OCs.1 These studies also imply that heterogeneity may
not necessarily be regulated only by gene expression or
protein synthesis but also by the organization and locali-
zation of proteins. However, further research on this topic
is required to improve the general understanding of cell
fusion.
We therefore designed a new study to test the hypothesis
that fusion of (pre)OCs is based on selectivity in the choice
of fusion partner within a heterogeneous population. We
used human (pre)OCs differentiated from CD14? periph-
eral blood cells and studied the characteristics of the
described fusion factors in order to reveal differences in
their function and localization. From our findings, we
propose that (pre)OCs are not just fusing at random but that
they specifically select their fusion partners on the basis of
complementarities.
Materials and Methods
Antibodies and Visualization of F-actin
The primary antibody mouse anti-human CD47 (clone
B6H12; BD, Franklin Lakes, NJ, USA) was used for both
functional blocking experiments and immunofluorescence
(IF) staining. For the control, we used mouse IgG1 isotype
control (BD). The following additional primary antibodies
were used for IF: mouse anti-human syncytin-1 clone 7E3
(a generous gift from Professor Lars-Inge Larsson and
Bolette Bjerregaard, PhD), rabbit anti-human DC-STAMP
(polyclonal C-17; Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) and goat anti-human CathepsinK (CatK,
polyclonal N-20; Santa Cruz Biotechnology Inc.). Sec-
ondary antibodies were as follows: Alexa Fluor 568 con-
jugated: goat anti-mouse, goat anti-rabbit, and donkey anti-
mouse, as well as Alexa Fluor 488 conjugated: rabbit anti-
goat and goat anti-rabbit (Invitrogen, Carlsbad, CA, USA).
Alexa Fluor 488 and 647 phalloidin (Invitrogen) were used
for visualization of F-actin.
Cell Culture
CD14? monocytes were purified from blood of human
donors (approved by the local ethical committee,
2007-0019) by centrifugation though Ficoll (Amersham,
GE Healthcare, Little Chalfont, United Kingdom) and
subsequent immunomagnetic isolation with MagCellect
Streptavidin Ferrofluid (R&D Systems, Minneapolis, MN,
USA). A more detailed experimental description has been
published previously [27]. Cells were cultured at 37 C in
5 % CO2, supplied with aMEM (Invitrogen) containing
10 % fetal calf serum (FCS) (Biological Industries, Kib-
butz Beit-Haemek, Israel) and 25 ng/ml macrophage
1 (Pre)OCs refers to a population of cells that consists of mixture of
preOCs and OCs.
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colony-stimulating factor (M-CSF, R&D Systems). After a
2-day culture period, the medium with FCS and M-CSF
was refreshed, and 25 ng/ml human receptor activator of
nuclear factor kappa-B ligand (RANKL, R&D Systems)
was added. The cells were subsequently seeded in either
8-well Lab-Tek chamber slides (Nunc, Roskilde, Denmark)
or 96-well plates (Greiner, Frickenhausen, Germany)
depending on the assay. Here we define preOCs as
mononucleated CD14? cells, and OCs are defined as
multinucleated cells differentiated from preOCs with
M-CSF and RANKL, as described above.
Functional Blocking
The cells were seeded in 96-well plates (7.5 9 104 cells per
well). After 2 days with M-CSF followed by 3 days with
both M-CSF and RANKL, the preOCs reached a very early
fusion stage (as identified by light microscopy). They were
then supplied with fresh medium containing M-CSF,
RANKL, and either one of the inhibitors or a corresponding
control supplement. The cells were subsequently cultured
for another 4 days. In the CD47 blocking experiment, the
preOCs were cultured with either 10 lg/ml CD47 antibody,
10 lg/ml mouse IgG1 isotype control antibody, or without
any additive. The medium with these supplements was
renewed every second day. In the Cx43-blocking experi-
ment, the preOCs were cultured with 100 lM 18a-glyc-
yrrhetinic acid (18a-GA, Sigma-Aldrich, St. Louis, MO,
USA) dissolved in DMSO, or with the corresponding vol-
ume of DMSO (0.2 %). The medium was renewed daily
with fresh conditioned medium (from a parallel running
(pre)OC culture) supplemented with 18a-GA or DMSO.
After 4 days of culture with inhibitors, the cells were fixed
and stained with Giemsa and May-Gru¨nwald as previously
described [28]. By analysis on an Axiovert 200 microscope
(Carl Zeiss, Oberkochen, Germany), all the multinucleated
OCs and their number of nuclei were counted systematically
in every second counting field in three replicate culture
wells for each treatment.
IF Staining
PreOCs were seeded in 8-well chamber slides (5–10 9 104
cells per well depending on the assay), and the medium with
RANKL was renewed after 3 days. After incubation with
RANKL for 5 days, the OCs were fixed and stained with the
CD47, DC-STAMP, or syncytin-1 antibodies listed above
and phalloidin, as previously described [5]; however, in this
case, the incubation time with primary antibody was 60 min.
If CD47-DC-STAMP or CD47-CatK double stainings were
performed, the cells were washed, incubated with each of
the primary antibodies consecutively, washed again, and
then incubated with both secondary antibodies simulta-
neously. Nuclei were visualized by mounting the cells in
ProLong Gold with DAPI (Invitrogen), and images were
obtained systematically with an Axio Imager Z1 microscope
(Carl Zeiss) with Isis software, version 5.3.1 (Metatsystems,
Altlussheim, Germany). The confocal analysis was per-
formed on an Olympus Fluoview FV10i microscope
(Olympus Corporation, Shinjuku, Tokyo, Japan), and ima-
ges were processed with Imaris version 7.3.1 (Bitplane AG,
Zurich, Switzerland).
Software, Data Analyses, and Statistics
The area measurement of CD47 immunostained (pre)OCs
on the obtained images was performed by ImageJ software
(National Institutes of Health, Bethesda, MD, USA). For
this measurement, two categories of (pre)OCs were defined
according to their CD47 status. The category of CD47-
positive cells included all (pre)OCs with CD47 in the
whole cell or concentrated in specific areas at the mem-
brane, while the negative category contained the CD47-
negative (pre)OCs and those with CD47 localized only
around the nuclei, because CD47 localized in this area is
expected to be insignificant for the fusion process. The
areas measured were defined as the two-dimensional areas
of the cells as measured from above. In case of the CD47-
DC-STAMP and CD47-CatK double stainings, images
were obtained, and all the cells were systematically eval-
uated for their status in regard to surface localization of
CD47 and DC-STAMP and their expression of CatK. All
graphs and statistics were performed by GraphPad Prism
software, version 4 (GraphPad Software, San Diego, CA,
USA), and statistical significance was defined as P \ 0.05.
The final figures were composed using CorelDraw X3
(Corel Corporation, Ottawa, Ontario, Canada).
Results
Blocking of Fusion Factors Affects Different Stages
in OC Fusion
To evaluate the function of CD47 and Cx43 in human OC
fusion, CD47 and Cx43 inhibitors were added to cultures of
preOC at an early differentiation stage, at which time
fusion had just started. Incubation of the preOCs with
CD47-blocking antibody resulted in an increased formation
of large nuclei-rich OCs, which were easily identified by
light microscopy (Fig. 1a). This finding was consistent in
four experiments. A comparison of the OCs treated with
CD47 antibody with those of control cultures revealed an
interesting distribution of the number of nuclei per OC: the
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proportion of OCs with six or more nuclei was significantly
different from the proportion of OCs with fewer nuclei.
While 26 and 29 % of the OCs in the control cultures had
six or more nuclei, this proportion reached 52 % of the
OCs treated with CD47 antibody (Fig. 1b).
To examine the role of Cx43 in OC fusion, we used the
inhibitor 18a-GA and compared the treated OCs with those
of a corresponding control culture. When fusing OCs were
treated with this inhibitor, significantly fewer of the large
OCs were formed, as opposed to an overweight of the
small binucleated OCs (Fig. 1c). These analyses show that
both 18a-GA and CD47 antibody have a fusion-stage-
dependent effect on OCs. However, while blocking of
CD47 seemed to favor the formation of large OCs and to
reduce the formation of the smaller OCs (Fig. 1b), the
Cx43 blockage had the opposite effect: it inhibited the
formation of OCs with four or more nuclei in favor of that
of smaller OCs (Fig. 1c). Our findings suggest heteroge-
neity in the population of fusing (pre)OCs. We therefore
investigated this further by analyzing the presence of
CD47 in such cells with the purpose of revealing any
heterogeneity in its localization.
CD47-presenting Cells have a Smaller Surface Area
To visualize the presence of CD47 in fusing (pre)OCs in
culture, and to supplement the results obtained by the
blocking of CD47, IF staining of CD47 and F-actin was
performed. Cells were fixed and stained at a point in time at
which fusion was ongoing and where both preOCs and OCs
at various fusion stages were observed. The staining
showed the presence of CD47 both in preOCs and OCs;
however, the most striking finding was that the cells pre-
senting CD47, either in the whole cell or at the cell
membrane, appeared to be relatively small (Fig. 2a). Many
bFig. 1 Blocking of fusion factors CD47 and Cx43 affects fusion of
OCs at different fusion stages. a Light microscopy images, at equal
magnification, of Giemsa-stained (pre)OC cultures incubated without
additives or with CD47-blocking antibody. b Relative distribution of
OCs according to treatment and their number of nuclei. For each
culture condition, counts from 3 different cultures were pooled,
ranked according to the number of nuclei per OC, and the percentages
of OCs with a given number of nuclei calculated. Fisher’s exact test
of the relation between culture condition and proportion of OCs with
6 or more nuclei compared to those with fewer nuclei: CD47
antibody–treated OCs versus both of the controls, P \ 0.0001 in both
tests; isotype control vs. control without additives, P = not signif-
icant. c Relative distribution of OCs in an 18a-GA-treated (pre)OC
culture and control according to their number of nuclei. Quantifica-
tions were done as in b. Fisher’s exact test of the relation between
culture condition and proportion of OCs with 2 nuclei compared to
those with 3 or more nuclei: 18a-GA-treated OCs vs. control,
P = 0.0007
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of these CD47-positive cells were rather compact, whereas
the large OCs with a widespread flat appearance were often
CD47 negative. In order to quantify the relevance of this
indicative finding, (pre)OCs were categorized according to
their CD47 status. A measurement of the area of (pre)OCs
positive for CD47 revealed that they had a significantly
smaller area than the CD47-negative cells (Fig. 2b). In
support of this finding, we also discovered that CD47-
positive OCs had significantly fewer nuclei than the CD47-
negative OCs (Fig. 2c). Together, these results indicate that
the CD47-presenting (pre)OCs are smaller than the CD47-
negative cells in terms of both their size and their number
of nuclei.
CD47 is Presented Early During OC Differentiation
The results displayed in Fig. 2 suggest that CD47 is pri-
marily found in small OCs with few nuclei.
To relate these findings to OC maturity in terms of
differentiation stage, we correlated the presence of CD47 to
that of OC differentiation markers DC-STAMP and CatK
in the individual (pre)OCs. Membrane-associated DC-
STAMP is well documented to be a marker of early OC
differentiation stages [26, 29], while CatK is a marker for
rather late stages [30]. We consider multinucleation of the
OCs to be an indicator of progressed differentiation, and
thereby we regard cells with several nuclei as more mature
than those with few. The (pre)OCs were analyzed for their
membrane localization of CD47 and DC-STAMP (Fig. 3a,
b), or their CD47 status was compared to CatK expression
(Fig. 3c, d). Analyses were done for each individual cell
using the described categorization. The results revealed
that the cells show comparable patterns of CD47 and DC-
STAMP presentation, with the highest prevalence of both
proteins in preOCs. The proportion of cells presenting
CD47 or DC-STAMP at their membrane declined among
the binucleated OCs and further among those with three or
more nuclei (Fig. 3a). Consistently, double staining of
CD47 and DC-STAMP showed that these factors are pri-
marily presented by the same (pre)OCs (Fig. 3b). Actually,
77 % of the CD47-positive (pre)OCs were also positive for
surface DC-STAMP (data not shown). On the contrary, the
corresponding comparison between CD47 and CatK in the
cells showed significantly different patterns of (pre)OCs
distribution according to number of nuclei. Because the
presence of CatK in the cells became more frequent with
their differentiation, the proportions of CatK presenting
(pre)OCs reached the highest level among those cells with
three or more nuclei (Fig. 3c). Consistently, only a little
overlap between CD47 and CatK presentation in the indi-
vidual (pre)OCs was found (Fig. 3d). Less than 28 % of all
CD47-positive cells in the analysis showed concurrent
expression of CatK (data not shown). Thus, the pattern of
Fig. 2 CD47 is preferentially found in (pre)OCs, which are small
both with respect to size and number of nuclei. a Staining of CD47
(red) and F-actin (green) in (pre)OCs differentiated for 5 days with
RANKL. Nuclei were visualized with DAPI (blue). b The cells
(seeding density: 5 9 104 per well) were assed for CD47 status. Then
the area of each cell in 8 culture wells was measured in square pixels,
and the sizes of the CD47-positive and CD47-negative cells were
compared. Paired t test, P = 0.0004. c Relative distribution of CD47-
positive and CD47-negative OCs according to their number of nuclei
was calculated as described under Fig. 1b. Fisher’s exact test of the
relation between CD47 status and proportion of OCs with 2 nuclei
compared to those with 3 or more, P = 0.0209
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CD47 presence among the (pre)OCs closely resembled that
described for their surface expression of DC-STAMP, and
thereby CD47 is characteristically related to (pre)OCs early
in their differentiation.
CD47 is Localized at the Interface Between Fusing
(pre)OCs
The use of confocal microscopy revealed in detail the
localization of CD47 in fusing (pre)OCs. Figure 4 shows
(pre)OCs interacting in close proximity, which strongly
indicates forthcoming fusion. In the examples shown in
Fig. 4a, b, CD47 was clearly concentrated at the part of the
preOC membrane facing the fusion partner in Fig. 4a in the
smaller of the two partners and in Fig. 4b in both partners.
From the cross-sectional representation in Fig. 4a, a clear
front of CD47 is revealed at the part of the preOC cell
membrane that is in contact with the fusion partner.
Heterogeneity in the Localization of the Fusion Factors
DC-STAMP and Syncytin-1
The heterogeneity in the presence of CD47 among cells at
different differentiation stages in (pre)OC culture and the
clear presentation of this protein at the interface of fusing
preOCs support the idea that CD47 is an important factor in
OC formation (Figs. 2, 3, 4). These findings led to related
studies of the localization of other known OC fusion factors.
For this purpose, the factors DC-STAMP and syncytin-1
were chosen because of their documented involvement in
OC fusion [5, 15–17]. Interestingly, heterogeneity was also
found in the expression and localization of these factors. IF
Fig. 3 Similar to the OC marker DC-STAMP, surface localization of
CD47 is primarily found among preOCs and OCs at early differen-
tiation stages (seeding density: 1 9 105 per well). a Distribution of
CD47- or DC-STAMP-positive (pre)OCs according to their number
of nuclei. Counts of (pre)OCs from 4 different CD47 and DC-STAMP
double-stained cultures were pooled, ranked according to the number
of nuclei per cell, and percentages calculated of (pre)OCs, with a
given number of nuclei, presenting CD47 or DC-STAMP in the
cellular membrane. Statistics: 2-way ANOVA, P = not significant.
b Distribution of all (pre)OCs analyzed according to their CD47 and
DC-STAMP status and their number of nuclei. Statistics: 2-way
ANOVA test of correlation between nuclei distribution and cell status
among 4 variable CD47/DC-STAMP cell phenotypes (±), (?/?),
(;), and (-/-), P \ 0.0001. c Distribution of CD47- or CatK-
positive (pre)OCs according to their number of nuclei. Data were
pooled from countings of (pre)OCs in 4 different CD47 and CatK
double-stained cultures. Cells were ranked according to their number
of nuclei and percentages calculated of CD47- or CatK-positive cells.
Statistics: 2-way ANOVA, P = 0.0005. d Distribution of all
(pre)OCs analyzed according to their CD47 and CatK status and
their number of nuclei. Statistics: 2-way ANOVA test of the
correlation between nuclei distribution and cell status among the 4
variable CD47/CatK cell phenotypes (±), (?/?), (;), and (-/-),
P \ 0.0001. Bonferroni posttests: statistical significance was defined
as *P \ 0.05, and ***P \ 0.001
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staining of F-actin, together with either DC-STAMP or
syncytin-1, revealed complementary protein localization
patterns in our (pre)OC cultures in both cases. Several of the
DC-STAMP-stained cells exerted a pattern of either absence
or of clear presence of this protein in the cellular membrane.
The results in Fig. 5a show examples of such DC-STAMP-
positive and -negative cells. The top pictures illustrate two
cells in close proximity. The DC-STAMP-positive partner
has a conformation resembling a phagocytic cup indicative
of fusion [5]. Likewise, staining of syncytin-1 showed het-
erogeneity in the localization of this protein. In this case,
opposite polarization of syncytin-1 in two fusion partners
was observed in several cells (Fig. 5b), which supports our
previously published findings [5]. Collectively, these results
indicate a pattern of diversity in the localization of several
known fusion factors between individual cells in a (pre)OC
culture.
Discussion
The aim of the present study was to explore how OCs choose
their fusion partners—a topic that until now has received
little attention. We hypothesized that heterogeneity among
(pre)OCs plays a role in their selection of fusion partners.
Through functional blocking of CD47 and Cx43, it was
suggested that OC fusion is differently affected depending
on the fusion stage of the cells. This indicated that not all
(pre)OCs express CD47, which could be confirmed through
double IF staining of CD47 and DC-STAMP (early marker)
or CatK (late marker). These stainings showed that CD47 is
preferentially found at early stages of OC differentiation and
they thereby match the results obtained by functional
blocking of CD47, which selectively reduced the number of
OCs with few nuclei. Another indication of heterogeneity
among the (pre)OCs was found in form of complementarity
Fig. 4 Visualization by confocal microscopy of CD47 in fusing
(pre)OCs. Staining of CD47 (red) and F-actin (green) in (pre)OCs
(1 9 105 per well) differentiated for 5 days with RANKL. Nuclei
were visualized with DAPI (blue). Z stacks along the x- and y-axes are
presented at bottom and on right side of images. a CD47 is localized
to the part of the cell membrane where a preOC is tightly interacting
with a binucleated OC. b Two preOCs in close proximity. Both show
strong CD47 signals at the part of their membrane facing the other
cell
Fig. 5 DC-STAMP and syncytin-1 are heterogeneously localized in
(pre)OCs. Visualization of DC-STAMP and syncytin-1 in (pre)OCs
(1 9 105 per well) differentiated for 5 days with RANKL. Nuclei
were visualized with DAPI (blue). a Staining of DC-STAMP (red)
and F-actin (green). b Staining of syncytin-1 (red) and F-actin
(green). Note pattern of heterogeneous localization of both these
proteins in cells in close proximity and opposite polarization of
syncytin-1 (arrows)
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in the localization of both syncytin-1 and DC-STAMP in
potential fusion partners. On the basis of these results, we
suggest that OC fusion is based on heterogeneity between
fusion partners.
Although our proposal for selectivity in OC fusion
depending on the differentiation stage of the cells is new, it
is supported by the literature. Mensah et al. [26] reported
that RANKL induces a mixed population of murine preOCs
with either high or low surface expression of DC-STAMP
and demonstrated that only in a co-culture of these two cell
populations did efficient fusion take place. Chiu et al. [29]
found that DC-STAMP was differentially expressed in
human OC cultures, and it was reported that OCs express
DC-STAMP early during differentiation but lose it when
they mature and become multinucleated, similar to what
we here report for CD47. This highlights that a known
fusion-related factor is differentially expressed in OC cul-
tures and that this favors fusion. We also show here that
DC-STAMP is preferentially expressed in early (pre)OCs
(Fig. 3a,b), which may also contribute to heterogeneity
between potential fusion partners (Fig. 5a). Similarly, we
previously reported that syncytin-1 was frequently con-
centrated at the part of the cell membrane where (pre)OCs
were facing their possible partners [5]. This is further
supported by our results here (Fig. 5b).
In addition to the syncytin-1 and DC-STAMP data, we
also found heterogeneity in terms of the presence or
absence of CD47 on the cell membrane of (pre)OCs. IF
staining showed that CD47 is primarily present in those
cells that are small, both in regard to area and number of
nuclei (Figs. 2, 3). Furthermore, CD47 presence on the cell
membrane was found to positively correlate with the pre-
sence of DC-STAMP early in the OC differentiation pro-
cess (Fig. 3b), while it correlated negatively with CatK
(Fig. 3d). This result is supported by a previous report
showing that CD47 was mainly expressed in mononucle-
ated macrophages, while it was down-regulated along with
multinucleation [10]. Taken together, these data highlight
the notion that CD47 is primarily expressed in less dif-
ferentiated (pre)OCs with few nuclei. This discovery may
be the key to understand the results of our CD47-blocking
experiment shown in Fig. 1, in which we found that
blocking of CD47 inhibited the generation of OCs with
fewer than six nuclei but favored the formation of large
OCs with six nuclei or more. At a first glance, we found
these results surprising because it was previously reported
that blocking or knocking out CD47 reduced fusion in both
mouse OC and rat macrophage cultures [9–11, 24].
However, in this context, it is important to consider the
elementary differences between our experimental approach
and those used in the aforementioned studies, as follows.
(1) The published data have been generated from studies
based on murine models both in vivo and in vitro. It is
indeed possible that the apparent lack of consistency
between our results and those available in the literature
may be explained by differences between human and
murine OCs in general and their culture conditions in
particular. It is in this aspect important to emphasize that
our cultures consist of purified CD14? cells from periph-
eral blood, while the studies on mouse cells were done
using unpurified bone marrow cultures. Such bone marrow
cultures do not only contain (pre)OCs but also other cells.
(2) The results obtained from CD47 knockout mice are not
consistent because Uluckan et al. [24] and Maile et al. [11]
did not find a decreased number of OCs in vivo, whereas
Lundberg et al. [9] did. (3) Previous studies were exclu-
sively based on analyses of the number of multinucleated
OCs (three or more nuclei) or the average number of nuclei
per OC. When OCs with two nuclei are excluded from such
an analysis, the very first fusion events is missed—and
thereby also valuable information when investigating
effects on fusion. This may indeed influence the results and
could, for example, mask specific details concerning the
fusion stage of the cells affected. In the present study, we
made a detailed analysis of the distribution of OCs
according to their number of nuclei (Fig. 1b), which has
not been reported before. (4) It is important to stress that
we did indeed observe an inhibition of OC fusion using the
CD47 antibody, although this was only observed for small
OCs. It is possible that the antibody shifts the balance of
the fusion process because the small CD47-positive cells
are prevented from fusing. The CD47-negative (pre)OCs
may therefore be forced to fuse with other CD47-negative
cells instead (which generally have more nuclei) (Figs. 2,
3). This results in an increased number of OCs with many
nuclei, although the reason for this was an inhibition. (5)
The addition of CD47 antibody was introduced already at
the beginning of the culture in the study of Lundberg et al.
[9], whereas we added it after 3 days with RANKL at the
onset of fusion. This may also affect the outcome of the
experiments differently.
On the basis of these issues, we conclude that hetero-
geneity in CD47 status between human (pre)OC plays an
important role in the selection of OC fusion partners. In
contrast to CD47, Cx43 appeared primarily to be involved
in the fusion of OCs with several nuclei. The addition of
the gap junction inhibitor 18a-GA to our (pre)OC cultures
resulted in a high proportion of small OCs, while the for-
mation of OCs with four or more nuclei was inhibited
(Fig. 1c). Kylma¨oja et al. [23] also used 18a-GA to inhibit
the formation of gap junctions in RAW 264.7- and mouse
bone marrow-derived cells seeded on bone slices. In sup-
port of our findings, they found a dose-dependent decrease
in the number of large, nuclei-rich OCs in the presence of
18a-GA. Other studies have also shown a role of gap
junctions in OC fusion [19, 20]. In summary, CD47 and
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Cx43 appear to affect fusion differently, and both support
the importance of heterogeneity in OC fusion.
Parallels may be drawn from our in vitro findings of
heterogeneity to physiological settings, where OC fusion
also takes place between cells with different characteris-
tics. Spatially distinct environments with different local
stimuli exist on the bone surface and in the bone marrow,
and the properties of the cells change as they move toward
and reach the bone surface where fusion takes place [31].
In general, heterogeneity between fusion partners is
broadly recognized and also essential in other biological
fusion processes [1–3]: cytotrophoblasts fuse with the
syncytiotrophoblast and show heterogeneous expression of
fusion factors [32–34], and myoblasts and myotubes that
fuse in muscle tissue show different characteristics both in
relation to motility and protein expression [35–37]. This
highlights the physiological relevance of our results.
In conclusion, we have shown that OC fusion is based
on heterogeneity between fusion partners. This emerging
concept may open new doors when exploring the enigma of
OC fusion.
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